Wednesday, July 22, 2015

Alzheimer: Clinical Trials Day at the AAIC2015 Conference

Alzheimer's Association Press Release at 0700 hrs EDT on 22 July 2015.

- Longer-Term Analysis of Phase 3 Solanezumab (Lilly) Up to 3.5 Years
- Biomarker Results from Phase 3 Gantenerumab (Roche) Trial
- New Data from Aducanumab (Biogen) Phase 1b Study

Video released by the Alzheimer's Association:
Video from press briefing

Article in The Guardian:

Scientists find first drug that appears to slow Alzheimer's disease
Solanezumab blocks memory loss in patients with mild version of the disease, making it the first medicine ever to slow pace of damage to patients’ brains

Read the article here


Post a Comment

<< Home